257 related articles for article (PubMed ID: 25541350)
1. A systematic review and meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC).
Arcangeli G; Arcangeli S; Strigari L
Crit Rev Oncol Hematol; 2015 Apr; 94(1):105-15. PubMed ID: 25541350
[TBL] [Abstract][Full Text] [Related]
2. Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials.
Arcangeli G; Strigari L; Arcangeli S
Crit Rev Oncol Hematol; 2015 Sep; 95(3):387-96. PubMed ID: 25934521
[TBL] [Abstract][Full Text] [Related]
3. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
[TBL] [Abstract][Full Text] [Related]
4. Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder-sparing approaches.
Koga F; Fujii Y; Masuda H; Numao N; Yokoyama M; Ishioka J; Saito K; Kawakami S; Kihara K
BJU Int; 2012 Sep; 110(6 Pt B):E203-8. PubMed ID: 22289431
[TBL] [Abstract][Full Text] [Related]
5. Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival.
Lee CY; Yang KL; Ko HL; Huang RY; Tsai PP; Chen MT; Lin YC; Hwang TI; Juang GD; Chi KH
Radiat Oncol; 2014 Sep; 9():213. PubMed ID: 25248470
[TBL] [Abstract][Full Text] [Related]
6. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Fahmy O; Khairul-Asri MG; Schubert T; Renninger M; Malek R; Kübler H; Stenzl A; Gakis G
Urol Oncol; 2018 Feb; 36(2):43-53. PubMed ID: 29102254
[TBL] [Abstract][Full Text] [Related]
7. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.
Ploussard G; Daneshmand S; Efstathiou JA; Herr HW; James ND; Rödel CM; Shariat SF; Shipley WU; Sternberg CN; Thalmann GN; Kassouf W
Eur Urol; 2014 Jul; 66(1):120-37. PubMed ID: 24613684
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
Efstathiou JA; Spiegel DY; Shipley WU; Heney NM; Kaufman DS; Niemierko A; Coen JJ; Skowronski RY; Paly JJ; McGovern FJ; Zietman AL
Eur Urol; 2012 Apr; 61(4):705-11. PubMed ID: 22101114
[TBL] [Abstract][Full Text] [Related]
9. Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy.
Krasnow RE; Drumm M; Roberts HJ; Niemierko A; Wu CL; Wu S; Zhang J; Heney NM; Wszolek MF; Blute ML; Feldman AS; Lee RJ; Zietman AL; Shipley WU; Efstathiou JA
Eur Urol; 2017 Jul; 72(1):54-60. PubMed ID: 28040351
[TBL] [Abstract][Full Text] [Related]
10. Significance of ERBB2 overexpression in therapeutic resistance and cancer-specific survival in muscle-invasive bladder cancer patients treated with chemoradiation-based selective bladder-sparing approach.
Inoue M; Koga F; Yoshida S; Tamura T; Fujii Y; Ito E; Kihara K
Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):303-11. PubMed ID: 25304790
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.
Mak RH; Hunt D; Shipley WU; Efstathiou JA; Tester WJ; Hagan MP; Kaufman DS; Heney NM; Zietman AL
J Clin Oncol; 2014 Dec; 32(34):3801-9. PubMed ID: 25366678
[TBL] [Abstract][Full Text] [Related]
12. Nomograms predicting response to therapy and outcomes after bladder-preserving trimodality therapy for muscle-invasive bladder cancer.
Coen JJ; Paly JJ; Niemierko A; Kaufman DS; Heney NM; Spiegel DY; Efstathiou JA; Zietman AL; Shipley WU
Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):311-6. PubMed ID: 23474117
[TBL] [Abstract][Full Text] [Related]
13. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
Kulkarni GS; Hermanns T; Wei Y; Bhindi B; Satkunasivam R; Athanasopoulos P; Bostrom PJ; Kuk C; Li K; Templeton AJ; Sridhar SS; van der Kwast TH; Chung P; Bristow RG; Milosevic M; Warde P; Fleshner NE; Jewett MAS; Bashir S; Zlotta AR
J Clin Oncol; 2017 Jul; 35(20):2299-2305. PubMed ID: 28410011
[TBL] [Abstract][Full Text] [Related]
14. High Ki-67 Expression Predicts Favorable Survival in Muscle-Invasive Bladder Cancer Patients Treated With Chemoradiation-Based Bladder-Sparing Protocol.
Tanabe K; Yoshida S; Koga F; Inoue M; Kobayashi S; Ishioka J; Tamura T; Sugawara E; Saito K; Akashi T; Fujii Y; Kihara K
Clin Genitourin Cancer; 2015 Aug; 13(4):e243-e251. PubMed ID: 25936588
[TBL] [Abstract][Full Text] [Related]
15. The Efficacy of Trimodal Chemoradiotherapy with Cisplatin as a Bladder-Preserving Strategy for the Treatment of Muscle-Invasive Bladder Cancer.
Nagao K; Hara T; Nishijima J; Shimizu K; Fujii N; Kobayashi K; Kawai Y; Inoue R; Yamamoto Y; Matsumoto H; Matsuyama H
Urol Int; 2017; 99(4):446-452. PubMed ID: 28628910
[TBL] [Abstract][Full Text] [Related]
16. Single institutional experience of bladder-preserving trimodality treatment for muscle-invasive bladder cancer.
Joung JY; Han KS; Kim TS; Seo HK; Chung J; Lee KH
J Korean Med Sci; 2008 Aug; 23(4):598-603. PubMed ID: 18756044
[TBL] [Abstract][Full Text] [Related]
17. Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients.
Koga F; Kihara K; Yoshida S; Yokoyama M; Saito K; Masuda H; Fujii Y; Kawakami S
BJU Int; 2012 Mar; 109(6):860-6. PubMed ID: 21854531
[TBL] [Abstract][Full Text] [Related]
18. A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvement.
Chiang Y; Cheng JC; Huang CY; Tsai YC; Lin CC; Hsu CH; Cheng AL; Pu YS
J Formos Med Assoc; 2017 Sep; 116(9):689-696. PubMed ID: 28034491
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of two prospective bladder-sparing trimodality approaches for invasive bladder cancer: neoadjuvant chemotherapy and concurrent radio-chemotherapy.
Zapatero A; Martin De Vidales C; Arellano R; Ibañez Y; Bocardo G; Perez M; Rabadan M; García Vicente F; Cruz Conde JA; Olivier C
Urology; 2012 Nov; 80(5):1056-62. PubMed ID: 22999456
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of systemic chemotherapy and intra-arterial chemotherapy with/without radiotherapy for bladder preservation or as neo-adjuvant therapy in patients with muscle-invasive bladder cancer: a single-centre study of 163 patients.
Miyata Y; Nomata K; Ohba K; Matsuo T; Hayashi N; Sakamoto I; Uetani M; Sakai H
Eur J Surg Oncol; 2015 Mar; 41(3):361-7. PubMed ID: 25312685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
